Health Care Innovation
Climate Change
Pandemics, Pollution, and Poppycock
By Henry I. Miller, M.S, M.D. and Andrew I. Fillat With the world in the grip of the COVID-19 pandemic, most of the short-term focus is now on how to avoid surges of infections and get the economy functioning so people can go back to work. Hindsight is, of course, ...
Commentary
ICER’s Cost Model Is Not Only Wrong It’s Also Dangerous
There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is ...
Commentary
The Savings Potential Of Biosimilars Is More Urgent Than Ever
It was not long ago that the economy’s rising tide was supporting state budgets across the country. As the Pew Charitable Trusts noted, widespread economic prosperity was supporting tax revenue growth and creating budget surpluses. When times are good, saving money is not always a priority in state capitols. But, times are ...
Blog
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...
Featured
NEW BRIEF: Expanding “Buy America” Rules Would Hurt U.S. Patients and Economy, Hinder Development of Coronavirus Vaccine
Expanding “Buy America” rules for prescription drugs and medical supplies would reduce patient access to drugs and further damage the economy, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “As the U.S. ...
Coronavirus
The Pat Miller Show Talks to Sally C. Pipes on Private Sector Role in Coronavirus Fight
Sally C. Pipes joined the the Pat Miller Show in Cincinnati, Ohio to discuss the enormous benefits of the American private sector in the fight against the coronavirus epidemic. Pipes breaks down how the private sector industries in the United States are pushing innovations in the fight against the coronavirus ...
Commentary
The Medicare Bureaucracy Is Unnecessarily Putting Kidney Patients At Risk
The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore alternatives to face-to-face triage and visits.” The CDC has issued this recommendation to help contain the spread of the virus, protect healthcare workers from ...
Drug Pricing
Sally C. Pipes Explains the Danger of Drug Price Controls with Coronavirus
PRI’s Sally C. Pipes, President, CEO, and Thomas W. Smith Fellow in Health Care Policy, joined the Kirby Nation to discuss the danger of drug price controls and American medical innovation. Pipes explains that roughly 4,500 new drugs are in various stage of development, with an estimated three-quarters of those ...
Commentary
In coronavirus battle, price controls would make it harder to develop lifesaving drugs
As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Blog
Single Payer Poll Watch: Coronavirus Update
Coronavirus is impacting everything and anything it touches. In the March PRI Single Payer Poll Watch, average opposition to a single payer plan overtook support, continuing the trend of growing opposition to a single payer health care plan PRI noticed in our first poll watch in December 2019. With the ...
Pandemics, Pollution, and Poppycock
By Henry I. Miller, M.S, M.D. and Andrew I. Fillat With the world in the grip of the COVID-19 pandemic, most of the short-term focus is now on how to avoid surges of infections and get the economy functioning so people can go back to work. Hindsight is, of course, ...
ICER’s Cost Model Is Not Only Wrong It’s Also Dangerous
There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is ...
The Savings Potential Of Biosimilars Is More Urgent Than Ever
It was not long ago that the economy’s rising tide was supporting state budgets across the country. As the Pew Charitable Trusts noted, widespread economic prosperity was supporting tax revenue growth and creating budget surpluses. When times are good, saving money is not always a priority in state capitols. But, times are ...
COVID-19 Reminds Us That Both Innovation and Affordability Are Needed
In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector ...
NEW BRIEF: Expanding “Buy America” Rules Would Hurt U.S. Patients and Economy, Hinder Development of Coronavirus Vaccine
Expanding “Buy America” rules for prescription drugs and medical supplies would reduce patient access to drugs and further damage the economy, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “As the U.S. ...
The Pat Miller Show Talks to Sally C. Pipes on Private Sector Role in Coronavirus Fight
Sally C. Pipes joined the the Pat Miller Show in Cincinnati, Ohio to discuss the enormous benefits of the American private sector in the fight against the coronavirus epidemic. Pipes breaks down how the private sector industries in the United States are pushing innovations in the fight against the coronavirus ...
The Medicare Bureaucracy Is Unnecessarily Putting Kidney Patients At Risk
The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore alternatives to face-to-face triage and visits.” The CDC has issued this recommendation to help contain the spread of the virus, protect healthcare workers from ...
Sally C. Pipes Explains the Danger of Drug Price Controls with Coronavirus
PRI’s Sally C. Pipes, President, CEO, and Thomas W. Smith Fellow in Health Care Policy, joined the Kirby Nation to discuss the danger of drug price controls and American medical innovation. Pipes explains that roughly 4,500 new drugs are in various stage of development, with an estimated three-quarters of those ...
In coronavirus battle, price controls would make it harder to develop lifesaving drugs
As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Single Payer Poll Watch: Coronavirus Update
Coronavirus is impacting everything and anything it touches. In the March PRI Single Payer Poll Watch, average opposition to a single payer plan overtook support, continuing the trend of growing opposition to a single payer health care plan PRI noticed in our first poll watch in December 2019. With the ...
